1-(3-methoxyphenyl)-3-[2-(methylthio)phenyl]urea is an organic compound with the following structure:
![Structure of 1-(3-methoxyphenyl)-3-[2-(methylthio)phenyl]urea](https://pubchem.ncbi.nlm.nih.gov/image/PNG/2D/2275771.png)
This compound is a derivative of urea, a common molecule found in many biological systems. The specific modifications to the urea backbone, with a 3-methoxyphenyl group attached to one nitrogen and a 2-(methylthio)phenyl group attached to the other, make this compound interesting for research.
**Importance in Research:**
This specific urea derivative is likely being studied for its potential **pharmacological activity**. Here's why:
* **Urea Analogs:** Urea analogs have been explored for various therapeutic applications. They can act as:
* **Enzyme inhibitors:** Blocking specific enzymes involved in disease processes.
* **Drug delivery agents:** Carrying other therapeutic molecules to their targets.
* **Antimicrobial agents:** Fighting bacterial or fungal infections.
* **Aromatic Substitutions:** The presence of aromatic groups (phenyl, methoxyphenyl, methylthiophenyl) in the molecule can influence its interactions with biological targets.
* **Improved binding:** Aromatic rings often contribute to binding affinity with biological receptors or enzymes.
* **Increased lipophilicity:** Aromatic groups can make the compound more soluble in fats, which can be important for membrane permeability.
* **Specific Research Targets:** Depending on the context of the research, this particular compound might be targeted for its potential effects on specific systems:
* **Central Nervous System:** The presence of aromatic groups can suggest activity in the brain.
* **Cardiovascular System:** Specific substitutions can influence interactions with receptors or enzymes involved in heart function.
* **Metabolic Processes:** The methoxy group can suggest interactions with enzymes involved in metabolism.
**To understand the true significance of this compound, more information is needed about:**
* **The specific research project:** What is the research question being addressed?
* **The desired biological activity:** What target is the compound being tested against?
* **Experimental data:** What are the results of the research involving this compound?
Without this information, it is difficult to definitively state the exact importance of 1-(3-methoxyphenyl)-3-[2-(methylthio)phenyl]urea.
ID Source | ID |
---|---|
PubMed CID | 6466475 |
CHEMBL ID | 1562836 |
CHEBI ID | 121717 |
Synonym |
---|
HMS2592N04 |
n-(3-methoxyphenyl)-n'-[2-(methylthio)phenyl]urea |
MLS000679449 , |
smr000297605 |
STK475122 |
1-(3-methoxyphenyl)-3-[2-(methylsulfanyl)phenyl]urea |
CHEBI:121717 |
AKOS003326840 |
1-(3-methoxyphenyl)-3-(2-methylsulfanylphenyl)urea |
CHEMBL1562836 |
1-(3-methoxyphenyl)-3-[2-(methylthio)phenyl]urea |
bdbm45609 |
cid_6466475 |
Q27210285 |
n-(3-methoxyphenyl)-n'-[2-(methylsulfanyl)phenyl]urea |
Class | Description |
---|---|
ureas | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 31.6228 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 16.9441 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 11.2202 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
TDP1 protein | Homo sapiens (human) | Potency | 23.7246 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 2.2387 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
pyruvate kinase | Leishmania mexicana mexicana | Potency | 22.3872 | 0.3981 | 13.7447 | 31.6228 | AID1721; AID1722 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 18.8876 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 22.3872 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 22.3872 | 0.5623 | 15.1609 | 31.6228 | AID1721 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 19.9526 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Coagulation factor XII | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0104 | 3.8890 | 10.9666 | AID852 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |